Biotechnology
Compare Stocks
5 / 10Stock Comparison
ATNM vs RAIN vs RNAC vs OESX vs IMVT
Revenue, margins, valuation, and 5-year total return — side by side.
Renewable Utilities
Biotechnology
Electrical Equipment & Parts
Biotechnology
ATNM vs RAIN vs RNAC vs OESX vs IMVT — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | |||||
|---|---|---|---|---|---|
| Industry | Biotechnology | Renewable Utilities | Biotechnology | Electrical Equipment & Parts | Biotechnology |
| Market Cap | $41M | $3M | $229M | $35M | $5.88B |
| Revenue (TTM) | $90K | $0.00 | $2M | $81M | $0.00 |
| Net Income (TTM) | $-23M | $-6M | $-152M | $-5M | $-464M |
| Gross Margin | 327.8% | — | -6.3% | 29.9% | — |
| Operating Margin | -283.5% | — | -51.4% | -4.3% | — |
| Total Debt | $2M | $4M | $13M | $10M | $98K |
| Cash & Equiv. | $48M | $33K | $125M | $6M | $714M |
ATNM vs RAIN vs RNAC vs OESX vs IMVT — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
| Stock | Jan 25 | May 26 | Return |
|---|---|---|---|
| Actinium Pharmaceut… (ATNM) | 100 | 112.9 | +12.9% |
| Rain Enhancement Te… (RAIN) | 100 | 34.0 | -66.0% |
| Cartesian Therapeut… (RNAC) | 100 | 44.8 | -55.2% |
| Orion Energy System… (OESX) | 100 | 125.1 | +25.1% |
| Immunovant, Inc. (IMVT) | 100 | 133.1 | +33.1% |
Price return only. Dividends and distributions are not included.
Quick Verdict: ATNM vs RAIN vs RNAC vs OESX vs IMVT
Each card shows where this stock fits in a portfolio — not just who wins on paper.
ATNM ranks third and is worth considering specifically for growth.
- 49.4% revenue growth vs RAIN's -121.2%
RAIN lags the leaders in this set but could rank higher in a more targeted comparison.
Among these 5 stocks, RNAC doesn't own a clear edge in any measured category.
OESX carries the broadest edge in this set and is the clearest fit for income & stability and growth exposure.
- Dividend streak 1 yrs, beta 1.03
- Rev growth -12.0%, EPS growth 0.0%, 3Y rev CAGR -13.8%
- Beta 1.03, current ratio 1.32x
- Beta 1.03 vs RNAC's 2.04
IMVT is the #2 pick in this set and the best alternative if long-term compounding and sleep-well-at-night is your priority.
- 190.9% 10Y total return vs OESX's -27.9%
- Lower volatility, beta 1.36, Low D/E 0.0%, current ratio 11.16x
- 3.2% margin vs ATNM's -260.8%
- +102.4% vs RAIN's -81.4%
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | 49.4% revenue growth vs RAIN's -121.2% | |
| Quality / Margins | 3.2% margin vs ATNM's -260.8% | |
| Stability / Safety | Beta 1.03 vs RNAC's 2.04 | |
| Dividends | Tie | None of these 5 stocks pay a meaningful dividend |
| Momentum (1Y) | +102.4% vs RAIN's -81.4% | |
| Efficiency (ROA) | -0.0% ROA vs RAIN's -298.9% |
ATNM vs RAIN vs RNAC vs OESX vs IMVT — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
Segment breakdown not available.
Segment breakdown not available.
ATNM vs RAIN vs RNAC vs OESX vs IMVT — Financial Metrics
Side-by-side numbers across 5 stocks — who leads on profitability, valuation, growth, and risk.
Who Leads Where
OESX leads in 4 of 6 categories
IMVT leads 1 • ATNM leads 0 • RAIN leads 0 • RNAC leads 0 • 1 tied
Explore the data ↓Income & Cash Flow (Last 12 Months)
OESX leads this category, winning 5 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
OESX and IMVT operate at a comparable scale, with $81M and $0 in trailing revenue. OESX is the more profitable business, keeping -5.6% of every revenue dollar as net income compared to ATNM's -260.8%. On growth, OESX holds the edge at +7.7% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | |||||
|---|---|---|---|---|---|
| RevenueTrailing 12 months | $90,000 | $0 | $2M | $81M | $0 |
| EBITDAEarnings before interest/tax | -$25M | -$5M | -$90M | -$1M | -$487M |
| Net IncomeAfter-tax profit | -$23M | -$6M | -$152M | -$5M | -$464M |
| Free Cash FlowCash after capex | -$23M | -$4M | -$77M | $348M | -$423M |
| Gross MarginGross profit ÷ Revenue | +3.3% | — | -6.3% | +29.9% | — |
| Operating MarginEBIT ÷ Revenue | -283.5% | — | -51.4% | -4.3% | — |
| Net MarginNet income ÷ Revenue | -260.8% | — | -85.5% | -5.6% | — |
| FCF MarginFCF ÷ Revenue | -255.4% | — | -43.6% | +4.3% | — |
| Rev. Growth (YoY)Latest quarter vs prior year | — | — | -92.9% | +7.7% | — |
| EPS Growth (YoY)Latest quarter vs prior year | +64.7% | — | -114.7% | +109.6% | +19.7% |
Valuation Metrics
OESX leads this category, winning 2 of 3 comparable metrics.
Valuation Metrics
| Metric | |||||
|---|---|---|---|---|---|
| Market CapShares × price | $41M | $3M | $229M | $35M | $5.9B |
| Enterprise ValueMkt cap + debt − cash | -$5M | $6M | $117M | $39M | $5.2B |
| Trailing P/EPrice ÷ TTM EPS | -1.20x | -0.55x | -1.72x | -2.74x | -10.60x |
| Forward P/EPrice ÷ next-FY EPS est. | — | — | — | — | — |
| PEG RatioP/E ÷ EPS growth rate | — | — | — | — | — |
| EV / EBITDAEnterprise value multiple | — | — | — | — | — |
| Price / SalesMarket cap ÷ Revenue | 456.68x | — | 81.98x | 0.44x | — |
| Price / BookPrice ÷ Book value/share | 5.22x | — | — | 2.73x | 6.20x |
| Price / FCFMarket cap ÷ FCF | — | — | — | 71.04x | — |
Profitability & Efficiency
OESX leads this category, winning 4 of 8 comparable metrics.
Profitability & Efficiency
OESX delivers a -0.0% return on equity — every $100 of shareholder capital generates $-0 in annual profit, vs $-2 for ATNM. IMVT carries lower financial leverage with a 0.00x debt-to-equity ratio, signaling a more conservative balance sheet compared to OESX's 0.87x. On the Piotroski fundamental quality scale (0–9), OESX scores 4/9 vs RNAC's 1/9, reflecting mixed financial health.
| Metric | |||||
|---|---|---|---|---|---|
| ROE (TTM)Return on equity | -2.2% | — | — | -0.0% | -47.1% |
| ROA (TTM)Return on assets | -43.4% | -3.0% | -45.1% | -0.0% | -44.1% |
| ROICReturn on invested capital | — | — | — | -34.8% | — |
| ROCEReturn on capital employed | -64.4% | — | -25.0% | -34.9% | -66.1% |
| Piotroski ScoreFundamental quality 0–9 | 3 | 3 | 1 | 4 | 2 |
| Debt / EquityFinancial leverage | 0.22x | — | — | 0.87x | 0.00x |
| Net DebtTotal debt minus cash | -$46M | $3M | -$112M | $4M | -$714M |
| Cash & Equiv.Liquid assets | $48M | $32,604 | $125M | $6M | $714M |
| Total DebtShort + long-term debt | $2M | $4M | $13M | $10M | $98,000 |
| Interest CoverageEBIT ÷ Interest expense | — | -148.90x | — | -3.29x | — |
Total Returns (Dividends Reinvested)
IMVT leads this category, winning 5 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in IMVT five years ago would be worth $18,445 today (with dividends reinvested), compared to $1,022 for RNAC. Over the past 12 months, IMVT leads with a +102.4% total return vs RAIN's -81.4%. The 3-year compound annual growth rate (CAGR) favors IMVT at 14.4% vs ATNM's -46.7% — a key indicator of consistent wealth creation.
| Metric | |||||
|---|---|---|---|---|---|
| YTD ReturnYear-to-date | -4.4% | -74.6% | +28.0% | -33.8% | +11.7% |
| 1-Year ReturnPast 12 months | -8.4% | -81.4% | -17.0% | +38.4% | +102.4% |
| 3-Year ReturnCumulative with dividends | -84.9% | -82.6% | -75.8% | -34.6% | +49.8% |
| 5-Year ReturnCumulative with dividends | -82.1% | -82.6% | -89.8% | -82.3% | +84.4% |
| 10-Year ReturnCumulative with dividends | -97.5% | -82.6% | -97.9% | -27.9% | +190.9% |
| CAGR (3Y)Annualised 3-year return | -46.7% | -44.2% | -37.7% | -13.2% | +14.4% |
Risk & Volatility
Evenly matched — OESX and IMVT each lead in 1 of 2 comparable metrics.
Risk & Volatility
OESX is the less volatile stock with a 1.03 beta — it tends to amplify market swings less than RNAC's 2.04 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. IMVT currently trades 96.2% from its 52-week high vs RAIN's 13.3% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | |||||
|---|---|---|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 1.32x | 1.20x | 2.04x | 1.03x | 1.36x |
| 52-Week HighHighest price in past year | $1.95 | $9.58 | $15.57 | $18.64 | $30.09 |
| 52-Week LowLowest price in past year | $0.95 | $1.27 | $5.60 | $5.50 | $13.36 |
| % of 52W HighCurrent price vs 52-week peak | +67.2% | +13.3% | +55.6% | +53.0% | +96.2% |
| RSI (14)Momentum oscillator 0–100 | 51.2 | 26.3 | 65.8 | 45.7 | 50.6 |
| Avg Volume (50D)Average daily shares traded | 185K | 20K | 223K | 39K | 1.4M |
Analyst Outlook
OESX leads this category, winning 1 of 1 comparable metric.
Analyst Outlook
Analyst consensus: RNAC as "Buy", IMVT as "Buy". Consensus price targets imply 85.0% upside for RNAC (target: $16) vs 57.2% for IMVT (target: $46).
| Metric | |||||
|---|---|---|---|---|---|
| Analyst RatingConsensus buy/hold/sell | — | — | Buy | — | Buy |
| Price TargetConsensus 12-month target | — | — | $16.00 | — | $45.50 |
| # AnalystsCovering analysts | — | — | 10 | — | 23 |
| Dividend YieldAnnual dividend ÷ price | — | — | — | — | — |
| Dividend StreakConsecutive years of raises | 0 | — | — | 1 | — |
| Dividend / ShareAnnual DPS | — | — | — | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | 0.0% | 0.0% | +0.0% | 0.0% |
OESX leads in 4 of 6 categories (Income & Cash Flow, Valuation Metrics). IMVT leads in 1 (Total Returns). 1 tied.
ATNM vs RAIN vs RNAC vs OESX vs IMVT: Key Questions Answered
8 questions · data-driven answers · updated daily
01Is ATNM or RAIN or RNAC or OESX or IMVT a better buy right now?
For growth investors, Orion Energy Systems, Inc.
(OESX) is the stronger pick with -12. 0% revenue growth year-over-year, versus -92. 8% for Cartesian Therapeutics, Inc. (RNAC). Analysts rate Cartesian Therapeutics, Inc. (RNAC) a "Buy" — based on 10 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — ATNM or RAIN or RNAC or OESX or IMVT?
Over the past 5 years, Immunovant, Inc.
(IMVT) delivered a total return of +84. 4%, compared to -89. 8% for Cartesian Therapeutics, Inc. (RNAC). Over 10 years, the gap is even starker: IMVT returned +190. 9% versus RNAC's -97. 9%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — ATNM or RAIN or RNAC or OESX or IMVT?
By beta (market sensitivity over 5 years), Orion Energy Systems, Inc.
(OESX) is the lower-risk stock at 1. 03β versus Cartesian Therapeutics, Inc. 's 2. 04β — meaning RNAC is approximately 97% more volatile than OESX relative to the S&P 500. On balance sheet safety, Immunovant, Inc. (IMVT) carries a lower debt/equity ratio of 0% versus 87% for Orion Energy Systems, Inc. — giving it more financial flexibility in a downturn.
04Which is growing faster — ATNM or RAIN or RNAC or OESX or IMVT?
By revenue growth (latest reported year), Orion Energy Systems, Inc.
(OESX) is pulling ahead at -12. 0% versus -92. 8% for Cartesian Therapeutics, Inc. (RNAC). On earnings-per-share growth, the picture is similar: Actinium Pharmaceuticals, Inc. grew EPS 14. 2% year-over-year, compared to -34. 9% for Rain Enhancement Technologies Holdco Inc. Over a 3-year CAGR, OESX leads at -13. 8% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
05Which has better profit margins — ATNM or RAIN or RNAC or OESX or IMVT?
Rain Enhancement Technologies Holdco Inc (RAIN) is the more profitable company, earning 0.
0% net margin versus -376. 5% for Actinium Pharmaceuticals, Inc. — meaning it keeps 0. 0% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: RAIN leads at 0. 0% versus -402. 7% for ATNM. At the gross margin level — before operating expenses — ATNM leads at 100. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
06Which pays a better dividend — ATNM or RAIN or RNAC or OESX or IMVT?
None of the stocks in this comparison currently pay a material dividend.
All are effectively zero-yield and should be held for capital appreciation rather than income.
07Is ATNM or RAIN or RNAC or OESX or IMVT better for a retirement portfolio?
For long-horizon retirement investors, Orion Energy Systems, Inc.
(OESX) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 1. 03)). Cartesian Therapeutics, Inc. (RNAC) carries a higher beta of 2. 04 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (OESX: -27. 9%, RNAC: -97. 9%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
08What are the main differences between ATNM and RAIN and RNAC and OESX and IMVT?
These companies operate in different sectors (ATNM (Healthcare) and RAIN (Utilities) and RNAC (Healthcare) and OESX (Industrials) and IMVT (Healthcare)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.
These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform all of them.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.